INTRODUCTION: We investigated the longitudinal relationship between cortical amyloid deposition, anxiety, and depression and the risk of incident mild cognitive impairment (MCI). METHODS: We followed 1440 community-dwelling, cognitively unimpaired individuals aged ≥ 50 years for a median of 5.5 years. Clinical anxiety and depression were assessed using Beck Anxiety and Depression Inventories (BAI, BDI-II). Cortical amyloid beta (Aβ) was measured by Pittsburgh compound B positron emission tomography (PiB-PET) and elevated deposition (PiB+) was defined as standardized uptake value ratio ≥ 1.48. We calculated Cox proportional hazards models with age as the time scale, adjusted for sex, education, and medical comorbidity. RESULTS: Cortical Aβ deposition (PiB+) independent of anxiety (BAI ≥ 10) or depression (BDI-II ≥ 13) increased the risk of MCI. There was a significant additive interaction between PiB+ and anxiety (joint effect hazard ratio 6.77; 95% confidence interval 3.58-12.79; P = .031) that is, being PiB+ and having anxiety further amplified the risk of MCI. DISCUSSION: Anxiety modified the association between PiB+ and incident MCI.

Department of Geriatrics Paracelsus Medical University Salzburg Austria

Department of Neurology Barrow Neurological Institute Phoenix Arizona USA

Department of Neurology Mayo Clinic Rochester Minnesota USA

Department of Quantitative Health Sciences Mayo Clinic Rochester Rochester Minnesota USA

Department of Radiology Mayo Clinic Rochester Minnesota USA

Institute of Sports and Sports Science Karlsruhe Institute of Technology Karlsruhe Germany

International Clinical Research Center St Anne Hospital Brno Czech Republic

Zobrazit více v PubMed

Jack CR Jr, Barrio JR, Kepe V. Cerebral amyloid PET imaging in Alzheimer's disease. Acta Neuropathol. 2013;126(5):643‐657. PubMed PMC

Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357‐367. PubMed

Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B. Ann Neurol. 2004;55(3):306‐319. PubMed

Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid‐beta but not tau Alzheimer's pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122‐131. PubMed PMC

Chetelat G, Villemagne VL, Pike KE, et al. Relationship between memory performance and beta‐amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis. 2012;10(1‐4):141‐144. PubMed

Knopman DS, Jack CR Jr, Wiste HJ, et al. Short‐term clinical outcomes for stages of NIA‐AA preclinical Alzheimer's disease. Neurology. 2012;78(20):1576‐1582. PubMed PMC

Petersen RC, Wiste HJ, Weigand SD, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73(1):85‐92. PubMed PMC

Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta‐amyloid measures and magnetic resonance imaging atrophy both predict time‐to‐progression from mild cognitive impairment to Alzheimer's disease. Brain : J Neurol. 2010;133(11):3336‐3348. PubMed PMC

Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221‐229. PubMed PMC

Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562. PubMed PMC

Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer's disease. Am J Geriatr Psychiatry. 2013;21(7):685‐695. PubMed PMC

Forrester SN, Gallo JJ, Smith GS, Leoutsakos JM. Patterns of neuropsychiatric symptoms in mild cognitive impairment and risk of dementia. Am J Geriatr Psychiatry. 2016;24(2):117‐125. PubMed PMC

Geda YE, Roberts RO, Mielke MM, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population‐based study. Am J Psychiatry. 2014. PubMed PMC

Pink A, Stokin GB, Bartley MM, et al. Neuropsychiatric symptoms, APOE epsilon4, and the risk of incident dementia: a population‐based study. Neurology. 2015;84(9):935‐943. PubMed PMC

Krell‐Roesch J, Lowe VJ, Neureiter J, et al. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the mayo clinic study of aging. Int Psychogeriatr. 2018;30(2):245‐251. PubMed PMC

Krell‐Roesch J, Vassilaki M, Mielke MM, et al. Cortical beta‐amyloid burden, neuropsychiatric symptoms, and cognitive status: the mayo clinic study of aging. Transl Psychiatry. 2019;9(1):123. PubMed PMC

Pietrzak RH, Lim YY, Neumeister A, et al. Amyloid‐beta, anxiety, and cognitive decline in preclinical Alzheimer's disease: a multicenter, prospective cohort study. JAMA Psychiatry. 2015;72(3):284‐291. PubMed

Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population‐based setting. JAMA Neurol. 2018;75(8):970‐979. PubMed PMC

Beck AT, Steer RA, Brown GK. BDI‐II, Beck Depression Inventory: Manual. 2nd ed. San Antonio, TX; Boston, MA: Psychological Corp.; Harcourt Brace; 1996.

Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893‐897. PubMed

Roberts RO, Geda YE, Knopman DS, et al. The mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58‐69. PubMed PMC

St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the rochester epidemiology project. Am J Epidemiol. 2011;173(9):1059‐1068. PubMed PMC

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183‐194. PubMed

Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412‐2414. PubMed

Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status: correlations with standardized psychometric testing. Arch Neurol. 1991;48(7):725‐728. PubMed

Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.

Wechsler D. Wechsler Memory Scale‐Revised. New York: The Psychological Corporation; 1987.

Kaplan E, Goodglass H, Brand S. Boston Naming Test. Philadelphia: Lea & Febiger; 1983.

Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271‐276.

Wechsler D. Wechsler Adult Intelligence Scale‐Revised. New York: Psychological Corporation; 1981.

Ivnik RJ, Malec JF, Smith GE, et al. Mayo's older Americans Normative Studies: WAIS‐R norms for ages 56 to 97. Clin Neuropsychol. 1992;6(sup001):1‐30.

Ivnik RJ, Malec JF, Smith GE, et al. Mayo's older Americans Normative Studies: WMS‐R norms for ages 56 to 94. Clin Neuropsychol. 1992;6(sup001):49‐82.

Ivnik RJ, Malec JF, Smith GE, et al. Mayo's older Americans Normative Studies: updated AVLT norms for ages 56 to 97. Clin Neuropsychol. 1992;6(sup001):83‐104.

Malec JF, Ivnik RJ, Smith GE, et al. Mayo's older Americans Normative Studies: utility of corrections for age and education for the WAIS‐R. Clin Neuropsychol. 1992;6(sup001):31‐47.

von Glischinski M, von Brachel R, Hirschfeld G. How depressed is “depressed”? A systematic review and diagnostic meta‐analysis of optimal cut points for the beck depression inventory revised (BDI‐II). Qual Life Res. 2019;28(5):1111‐1118. PubMed

Morin CM, Landreville P, Colecchi C, McDonald K, Stone J, Ling W. The beck anxiety inventory: psychometric properties with older adults. J Clin Geropsychology. 1999;5(1):19‐29.

Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's Dement. 2017;13(3):205‐216. PubMed PMC

Lowe VJ, Kemp BJ. Comparison of 18F‐FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50(6):878‐886. PubMed PMC

Klunk WE, Koeppe RA, Price JC, et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer's Dement. 2015;11(1):1–15 e11‐14. PubMed PMC

Jack CR Jr, Wiste HJ, Therneau TM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316‐2325. PubMed PMC

Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. J Clin Epidemiol. 1992;45(6):613‐619. PubMed

Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Gaithersburg, Md: Aspen; 2000.

Becker E, Orellana Rios CL, Lahmann C, Rucker G, Bauer J, Boeker M. Anxiety as a risk factor of Alzheimer's disease and vascular dementia. Br J Psychiatry. 2018;213(5):654‐660. PubMed

Babulal GM, Ghoshal N, Head D, et al. Mood changes in cognitively normal older adults are linked to Alzheimer's disease biomarker levels. Am J Geriatr Psychiatry. 2016;24(11):1095‐1104. PubMed PMC

Donovan NJ, Locascio JJ, Marshall GA, et al. Longitudinal association of amyloid beta and anxious‐depressive symptoms in cognitively normal older adults. Am J Psychiatry. 2018;175(6):530‐537. PubMed PMC

Gatchel JR, Rabin JS, Buckley RF, et al. Longitudinal association of depression symptoms with cognition and cortical amyloid among community‐dwelling older adults. JAMA Netw Open. 2019;2(8):e198964. PubMed PMC

Johansson M, Stomrud E, Lindberg O, et al. Apathy and anxiety are early markers of Alzheimer's disease. Neurobiol Aging. 2020;85:74‐82. PubMed

Steffens DC, Byrum CE, McQuoid DR, et al. Hippocampal volume in geriatric depression. Biol Psychiatry. 2000;48(4):301‐309. PubMed

Koolschijn PC, van Haren NE, Lensvelt‐Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta‐analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30(11):3719‐3735. PubMed PMC

Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimer's Dement. 2013;9(5):602‐608. PubMed PMC

St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ 3rd, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the rochester epidemiology project. Mayo Clin Proc. 2012;87(2):151‐160. PubMed PMC

Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline